L

Louisiana Heart Center | Slidell, LA

Research site

(Unclaimed)

Location

1810 Linberg Drive, Suite 2100, Slidell, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Apixaban

Evolocumab

Obicetrapib

IONIS-AGT-LRx

Milvexian

Iron

BI 690517

BMS-512148

Dapagliflozin

Ranolazine

Parent organization

This site is a part of Louisiana Heart Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 15 total trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: Empagliflozin

Drug: BI 690517

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting

Coronary Heart Disease (CHD)

Drug: Evolocumab

Drug: Placebo